183 related articles for article (PubMed ID: 3910219)
1. Preclinical studies identifying carboplatin as a viable cisplatin alternative.
Harrap KR
Cancer Treat Rev; 1985 Sep; 12 Suppl A():21-33. PubMed ID: 3910219
[TBL] [Abstract][Full Text] [Related]
2. Preclinical antitumor and toxicologic profile of carboplatin.
Rose WC; Schurig JE
Cancer Treat Rev; 1985 Sep; 12 Suppl A():1-19. PubMed ID: 3910215
[TBL] [Abstract][Full Text] [Related]
3. Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9).
Schweitzer VG; Rarey KE; Dolan DF; Abrams G; Litterst CJ; Sheridan C
Otolaryngol Head Neck Surg; 1986 Apr; 94(4):458-70. PubMed ID: 3086808
[TBL] [Abstract][Full Text] [Related]
4. Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin.
Bregman CL; Williams PD
Cancer Chemother Pharmacol; 1986; 18(2):117-23. PubMed ID: 3539384
[TBL] [Abstract][Full Text] [Related]
5. Lung tumour growth delay and normal tissue toxicity induced by three cytotoxic platinum drugs.
van Rongen E; Kal HB; Kuijpers WC; van Berkel AH
Strahlenther Onkol; 1992 May; 168(5):300-7. PubMed ID: 1598667
[TBL] [Abstract][Full Text] [Related]
6. Cycloplatam and oxoplatin--the new antitumor platinum compounds of the second generation.
Presnov MA; Konovalova AL
Arch Geschwulstforsch; 1988; 58(1):43-9. PubMed ID: 3285804
[TBL] [Abstract][Full Text] [Related]
7. Effect of oxoplatinum and CBDCA on renal functions in rats.
Láznícková A; Semecký V; Láznícek M; Zubr V; Koksál J; Kvĕtina J
Neoplasma; 1989; 36(2):161-9. PubMed ID: 2654665
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP).
Kralovánszky J; Prajda N; Kerpel-Fronius S; Gál F; Kiss F
Cancer Chemother Pharmacol; 1988; 21(1):40-4. PubMed ID: 3277733
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
[TBL] [Abstract][Full Text] [Related]
11. Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.
Steerenberg PA; Vendrik CP; de Jong WH; de Groot G; Fichtinger-Schepman AM; Scheefhals AP; Schornagel JH
Cancer Chemother Pharmacol; 1988; 22(1):51-7. PubMed ID: 3293840
[TBL] [Abstract][Full Text] [Related]
12. Preclinical toxicology of platinum analogues in dogs.
Lelieveld P; van der Vijgh WJ; van Velzen D
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1147-54. PubMed ID: 3308482
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives.
Lelieveld P; Van der Vijgh WJ; Veldhuizen RW; Van Velzen D; Van Putten LM; Atassi G; Danguy A
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1087-104. PubMed ID: 6381064
[TBL] [Abstract][Full Text] [Related]
14. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow.
Prajda N; Kralovánszky J; Gal F; Kiss F; Kerpel-Fronius S
In Vivo; 1989; 3(4):267-70. PubMed ID: 2519864
[TBL] [Abstract][Full Text] [Related]
16. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.
Calvert AH; Harland SJ; Newell DR; Siddik ZH; Jones AC; McElwain TJ; Raju S; Wiltshaw E; Smith IE; Baker JM; Peckham MJ; Harrap KR
Cancer Chemother Pharmacol; 1982; 9(3):140-7. PubMed ID: 6761010
[TBL] [Abstract][Full Text] [Related]
17. Vestibular morphological analysis of the effects of cisplatin vs. platinum analogs, CBDCA (JM-8) and CHIP (JM-9).
Schweitzer VG; Rarey KE; Dolan DF; Abrams GE; Sheridan C
Laryngoscope; 1986 Sep; 96(9 Pt 1):959-74. PubMed ID: 3528727
[TBL] [Abstract][Full Text] [Related]
18. [Study on nephrotoxicity in rats receiving cis-diammine-1,1-cyclobutane dicarboxylate platinum II--special reference to morphological changes].
Kimura S; Nakajima Y; Hasegawa S; Tazaki H
Nihon Hinyokika Gakkai Zasshi; 1989 Apr; 80(4):517-25. PubMed ID: 2664296
[TBL] [Abstract][Full Text] [Related]
19. The effect of diethyldithiocarbamate on the haematological toxicity and antitumour activity of carboplatin.
Dible SE; Siddik ZH; Boxall FE; Harrap KR
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):813-8. PubMed ID: 2820745
[TBL] [Abstract][Full Text] [Related]
20. [Preclinical and clinical evaluation of toxicity and antitumor activity of cisplatin analogues].
Ariyoshi Y; Ota K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1379-85. PubMed ID: 2658826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
